Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib + trastuzumab + oxaliplatin-based chemotherapy or pembrolizumab for HER2-positive gastrointestinal cancers
jRCT2031220143Phase 2Active, not recruiting
- Sponsor
- Seagen Inc.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of tucatinib in colorectal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 3 more (9 cohorts), sponsored by Seagen Inc. Primary endpoints: Incidence of renal dose-limiting toxicities (DLTs) (Cohorts 1A and 1B, not applicable in Japan), Safety and tolerability (Cohorts 1C, 1E, 1F, 1G) and 2 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
colorectal adenocarcinomagastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on jRCT2031220143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220143.